Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis.
The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interpretation. Additional studies of recombinant activated protein C (rhAPC) have added to our understanding about this drug and to controversy as well. So how do we deal with rhAPC use in our clinical practice?
Dellinger
R Phillip
RP
Section of Critical Care Medicine, Cooper University Hospital, One Cooper Plaza, Camden, NJ 08103, USA. dellinger-phil@cooperhealth.edu
D006801:Humans; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000401:mortality*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000401:mortality
D011486:Protein C; D011994:Recombinant Proteins